Jun 2026 (Q2 FY26) — Aug 12, 2026
Altimmune Q2 FY26 — MASH Phase 3 Initiated, Strong AUD Phase 2 Data
Read the full callAltimmune (ALT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Altimmune earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -22.8 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.36 +2.16% · +$0.05
Performance −40.6% 1Y
1Y: $3.97 on 14 Oct 2025 → $2.36. High $6.18 (27 Jan 2026), low $2.31 (14 Oct 2026).
- Previous close
- $2.31
- 52-week range
- $2.31 – $6.18
- One year
- −41.00%
Overview
- Symbol
- ALT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Altimmune earnings calls (ALT)
Financials
What the filings say
Net profit, year on year: −3% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Operating profit | -25 | -25 | -22 | -23 | -21 | -29 | -24 | -26 |
| Operating margin | −495340.0% | −497320.0% | −436300.0% | −458440.0% | −417180.0% | −111126.9% | — | — |
| Other income | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | -23 | -23 | -20 | -22 | -19 | -27 | -23 | -23 |
| Tax rate | 0.0% | — | 3.4% | — | — | 0.0% | — | — |
| Net profit | -23 | -23 | -20 | -22 | -19 | -27 | -23 | -23 |
| EPS ($ per share) | -0.32 | — | -0.26 | -0.27 | -0.21 | — | -0.18 | -0.12 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -117 | -137 | -186 | -293 | -378 | -466 | -561 | -649 |
| Total liabilities | 6 | 9 | 19 | 20 | 22 | 17 | 16 | 55 |
| Fixed assets | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Investments | — | 28 | 100 | — | 74 | 63 | 95 | 230 |
| Total assets | 55 | 54 | 245 | 219 | 207 | 211 | 139 | 280 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9 | -10 | -34 | -78 | -63 | -76 | -80 | -68 |
| Cash from investing | -1 | -28 | -72 | 88 | -73 | 14 | -28 | -132 |
| Cash from financing | 32 | 13 | 213 | 65 | 57 | 86 | 10 | 207 |
| Net cash flow | 22 | -25 | 107 | 74 | -79 | 24 | -98 | 7 |
| Capital expenditure | -1 | -0 | -0 | -12 | -0 | -0 | — | -0 |
| Free cash flow | -10 | -10 | -35 | -90 | -63 | -76 | — | -68 |
Insider filings
44 filings between Nov 11, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
$370.0K
11 purchases by 6 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 5
- Award — granted as compensation
- 14
- Option exercise — converted options into shares
- 14
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Durso Jerome Benedict | $213.7K | — | Aug 13, 2026 |
| GILL JOHN | $82.6K | — | Apr 6, 2026 |
| WEAVER GREGORY L | $49.2K | — | Apr 1, 2026 |
| Pisano Wayne | $20.4K | — | Jan 8, 2026 |
| Sohn Catherine A. | $2.1K | — | Jan 5, 2026 |
| Jorkasky Diane | $2.0K | — | Dec 29, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | WEAVER GREGORY L Chief Financial Officer | Tax withheld | 4,379 | $12.1K |
| Oct 1, 2026 | Arbet-Engels Christophe Chief Medical Officer | Tax withheld | 12,679 | $35.0K |
| Oct 1, 2026 | Arbet-Engels Christophe Chief Medical Officer | Option exercise | 37,500 | $0 |
| Oct 1, 2026 | WEAVER GREGORY L Chief Financial Officer | Option exercise | 14,475 | $0 |
| Sep 16, 2026 | Richardson Linda M Chief Commercial Officer | Option exercise | 24,000 | $0 |
| Sep 16, 2026 | Richardson Linda M Chief Commercial Officer | Tax withheld | 6,826 | $22.1K |
| Aug 13, 2026 | Durso Jerome Benedict President and CEO | Purchase | 15,000 | $44.3K |
| Jul 31, 2026 | Roberts M Scot Chief Scientific Officer | Award | 875 | $2.1K |
| Jul 31, 2026 | WEAVER GREGORY L Chief Financial Officer | Award | 1,753 | $4.2K |
| Apr 6, 2026 | GILL JOHN Director | Purchase | 9,200 | $31.3K |
| Apr 1, 2026 | Durso Jerome Benedict President and CEO | Purchase | 15,000 | $47.1K |
| Apr 1, 2026 | WEAVER GREGORY L Chief Financial Officer | Purchase | 10,000 | $31.5K |
| Mar 6, 2026 | Durso Jerome Benedict President and CEO | Purchase | 20,000 | $70.8K |
| Mar 6, 2026 | WEAVER GREGORY L Chief Financial Officer | Purchase | 5,000 | $17.7K |
| Feb 2, 2026 | Roberts M Scot Chief Scientific Officer | Tax withheld | 2,329 | $12.9K |
| Feb 2, 2026 | Roberts M Scot Chief Scientific Officer | Option exercise | 7,775 | $0 |
| Jan 31, 2026 | Roberts M Scot Chief Scientific Officer | Award | 5,567 | $17.1K |
| Jan 31, 2026 | Jordt Raymond M Chief Business Officer | Award | 4,571 | $14.0K |
| Jan 31, 2026 | Garg Vipin K Director | Award | 6,926 | $21.3K |
| Jan 30, 2026 | Roberts M Scot Chief Scientific Officer | Option exercise | 9,275 | $0 |
| Jan 30, 2026 | Roberts M Scot Chief Scientific Officer | Tax withheld | 2,859 | $16.0K |
| Jan 30, 2026 | Garg Vipin K Director | Tax withheld | 11,632 | $65.1K |
| Jan 30, 2026 | Garg Vipin K Director | Option exercise | 26,775 | $0 |
| Jan 27, 2026 | Roberts M Scot Chief Scientific Officer | Option exercise | 15,850 | $0 |
| Jan 27, 2026 | Roberts M Scot Chief Scientific Officer | Tax withheld | 4,748 | $29.3K |
| Jan 27, 2026 | Jordt Raymond M Chief Business Officer | Option exercise | 15,850 | $0 |
| Jan 27, 2026 | Jordt Raymond M Chief Business Officer | Tax withheld | 4,229 | $26.1K |
| Jan 27, 2026 | Garg Vipin K Director | Option exercise | 41,200 | $0 |
| Jan 27, 2026 | Garg Vipin K Director | Tax withheld | 17,898 | $110.6K |
| Jan 25, 2026 | Roberts M Scot Chief Scientific Officer | Tax withheld | 4,373 | $24.1K |
| Jan 25, 2026 | Jordt Raymond M Chief Business Officer | Tax withheld | 3,855 | $21.2K |
| Jan 25, 2026 | Jordt Raymond M Chief Business Officer | Option exercise | 14,600 | $0 |
| Jan 25, 2026 | Garg Vipin K Director | Tax withheld | 17,984 | $98.9K |
| Jan 25, 2026 | Roberts M Scot Chief Scientific Officer | Option exercise | 14,600 | $0 |
| Jan 25, 2026 | Garg Vipin K Director | Option exercise | 42,050 | $0 |
| Jan 8, 2026 | Pisano Wayne Director | Purchase | 5,000 | $20.4K |
| Jan 5, 2026 | Sohn Catherine A. Director | Purchase | 500 | $2.1K |
| Jan 1, 2026 | Jordt Raymond M Chief Business Officer | Tax withheld | 2,475 | $8.9K |
| Jan 1, 2026 | Jordt Raymond M Chief Business Officer | Option exercise | 9,375 | $0 |
| Dec 29, 2025 | Jorkasky Diane Director | Purchase | 527 | $2.0K |
| Dec 23, 2025 | GILL JOHN Director | Purchase | 12,500 | $51.2K |
| Dec 22, 2025 | Durso Jerome Benedict Director | Purchase | 12,500 | $51.6K |
| Nov 11, 2025 | WEAVER GREGORY L Chief Financial Officer | Option exercise | 18,750 | $0 |
| Nov 11, 2025 | WEAVER GREGORY L Chief Financial Officer | Tax withheld | 5,672 | $24.3K |
| Jul 31, 2025 | Jordt Raymond M Chief Business Officer | Award | 1,368 | $4.3K |
| Jul 31, 2025 | Roberts M Scot Chief Scientific Officer | Award | 846 | $2.7K |
| Jul 31, 2025 | Harris Matthew Scott Chief Medical Officer | Award | 2,018 | $6.3K |
| Mar 17, 2025 | Sohn Catherine A. Director | Purchase | 1,000 | $5.8K |
| Mar 13, 2025 | WEAVER GREGORY L Chief Financial Officer | Purchase | 10,000 | $52.0K |
| Mar 7, 2025 | Harris Matthew Scott Chief Medical Officer | Gift | 67,787 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Altimmune, Inc.
Free account. Everything above stays public.
Write why you follow Altimmune, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading